Introduction
In recent years, it has been discovered that lysine methylation, which was initially identified on histone proteins, occurs on a wide range of non-histone proteins,w here it plays essential regulatory roles in variousc ellularp rocesses. [1] [2] [3] [4] Lysine residues can be mono-, di-and trimethylated and the biological outcome of the modificationd epends on the site and degree of methylation in target proteins. Lysine methylation is introduced by protein lysine methyltransferases (PKMTs) [5, 6] including enzymes of the SET and MYND-containing protein (SMYD) family. [6] [7] [8] The biological functiono fS MYD PKMTsi sd iverse including gene regulation, chromatin remodeling, transcription, signal transduction, cell cycle control, and DNA damage response. [6] [7] [8] The SMYD PKMT family consists of five members, called SMYD1 to 5. They share their structurald omain architecture with other SET domain PKMTs, where ac atalytically active SET domain containing aS ET-I insertion involved in targetp eptide interaction is followed by aP ost-SET domain. Different from other SET domain PKMTs, the SET domain of SMYD family enzymes is further splitb yt he insertion of aM YND (Myeloid-Nervey-DEAF-1) domain betweent he initial part of the SET domain (the S-sequence) andt he SET-I part. The MYND domain is az inc-finger domain that mediates protein-protein interactions. Different from other SET-domainP KMTs, the SMYD family enzymes do not contain aP re-SET domain, but they carry an additional SMYD family specific C-terminal domain (CTD).
The SMYD2e nzyme( also called KMT3C) was initially discovered as an H3K36 dimethyltransferase and SMYD2 activity had been shown to lead to repression of transcribed genes. [9] Later it was found that SMYD2 also methylates H3K4 in the presence of the HSP90 protein. [10] In addition to the methylation of histone targets, SMYD2 was reported to methylate several nonhistonep roteins like p53 [11] and the retinoblastoma protein (RB). [12] TP53 is one of the most studied tumor suppressor genes and ith as importantb iological functions in the regulation of cell cycle arrest, apoptosis and the DNA damage response. Four lysine residues in the C-terminalp art of p53 can be methylated by different PKMTs leadingt od istinct biological outputs. [13] Methylation studies with p53 lysine to arginine mutants revealed that K370i sthem ain methylation site of SMYD2 on p53. [11] Methylationo fK 370 results in repression of p53 regulated transcription and p53 mediated apoptosis in cancer cells due to decreased occupancy of methylated p53 at The SMYD2 protein lysine methyltransferase methylates various histonea nd non-histone proteins and is overexpressed in several cancers. Using peptidea rrays, we investigated the substrate specificityo ft he enzyme, revealing ar ecognition of leucine (or weaker phenylalanine) at the À1p eptides ite and disfavor of acidic residuesa tt he + 1t o+ 3s ites. Using this motif, novel SMYD2p eptide substrates were identified, leading to the discovery of 32 novel peptides ubstrates with av alidated target site. Amongt hem, 19 were previously reported to be methylated at the target lysine in human cells, stronglys uggesting that SMYD2 is the protein lysine methyltransferase re-sponsiblef or this activity.M ethylation of some of the novel peptides ubstrates was tested at the protein level, leadingt o the identification of 14 novel protein substrates of SMYD2, six of which were more strongly methylated than p53, the best SMYD2 substrate described so far.T he novel SMYD2 substrate proteins are involved in diverse biological processes such as chromatin regulation, transcription, and intracellular signaling. The results of our study provide afundament forfuture investigationsinto the role of this important enzyme in normaldevelopment and cancer.
its targetg enes. [11, 12] Different studies reported that methylation of p53 by SMYD2w as highert han methylation of the other identified histonet argets. [14] [15] [16] The retinoblastoma tumor suppressor protein (RB) involved in the regulation of cell cycle progression and apoptosis is another non-histone substrate of SMYD2 with as trong cancer connection.S MYD2 methylation of RB occurs at lysine 860, leadingt ot he progression of the cell cycle via differentm olecular pathways. [17] Moreover, SMYD2 also methylates the estrogen receptor alpha (ERa)p rotein at lysine 266 repressing ERa transactivation activity. [18] Details of the substrate peptide recognition of SMYD2 have been identified by two structures of the enzyme with the p53 and the ERa peptide substrates. [14, 19] In addition, several other nonhistonet argets werei dentified in the last coupleo fy ears, including PARP1, [20] MAPKAPK3 [21] and PTEN. [22] SMYD2 is essential for normalo rganismal development [6] [7] [8] and dysregulation of SMYD2 was found in cardiovascular disease and cancer. [6] [7] [8] For example, SMYD2 is significantly overexpressed in many cancers including esophageal squamousc ell carcinoma (ESCC), bladder and gastric cancer, [23, 24] and in triple negative breast cancer it was shown to have at umor promoting effect. [8] In some cases, the molecular mechanismsconnecting the methylation of SMYD2 non-histone substrates and oncogenic effects have been discovered and, based on these, inhibitors of SMYD2 have been tested as therapeutic agents. [24] Better understanding of the biology of the SMYD2 protein lysine methylation signaling network critically dependso nt he identification of the substrate profile of SMYD2, but in spite of progress in this direction, the identification of PKMT substrates is not trivial. [25] General proteome-wide screenings were undertaken aiming to identify SMYD2 substrates in an unbiased way. By combiningp roteomic lysine methylation data with SMYD2 knock-down, 34 SMYD2 dependentm ethylation events were discoveredi nh uman cell lines, two of which were validated by in vitro methylation experiments (AHNAKa nd AHNAK2). [26] In an approach combining enzyme specificity and modelling, four novel SMYD2 substrates (SIX1, SIX2,S IN3B and DHX15) were discovereda nd validated. [27] Another bioinformatic approach combining different data sources like knowns ubstrates, proteomic data, protein interaction, gene ontology ands tructural data has led to the identification of six novel substrates (MAPT, CCAR2,E EF2, NCOA3,S TUB1 and UTP14A). [28] In the current study,w ea lso applieda nu nbiaseds earch for novel SMYD2 substrates. In our workflow, the substrate specificity of SMYD2 is analyzed by methylation of peptide arrays to identify additional non-histone targets in as ystematic manner.D ifferent studies already showed that the analysiso ft he specificity profiles of PKMTsi sapowerful method to investigate their substrate recognition and based on this discover novel substrates. [25, [29] [30] [31] [32] [33] [34] [35] With this approach, we identified 32 novel peptide substrates of SMYD2 with validated methylation sites. Amongt hem, 14 novel non-histone protein substrates of SMYD2 were discovered, six of which were more strongly methylatedt han p53, the best SMYD2s ubstrate described so far. Then ovel SMYD2s ubstratesa re involved in diversec ellularp rocesses like chromatini nteraction andm odification, gene regulation,DNA repair,actin filament dynamics,and Rassignaling.
Results and Discussion
As described above, it is ab ig challenge to link protein lysine methyltransferases with lysine methylation eventso fs pecific substrates. In this study,w ewanted to analyze the substrate sequence specificity of SMYD2 in detail using ap eptidea rray approach. Afterward, we used the specificity information to search for and validate additional non-histone substrates of SMYD2 thatw ill give deeper insighti nto the wide substrate spectrum of SMYD2 and the connected biological functions.
Protein expression and catalyticactivity of SMYD2o np 53-K370
Full-length SMYD2 and p53 were expressed as GST-fusion proteins in Escherichia coli cells and purified by affinity chromatography ( Figure 1A ). The circular dichroism (CD) spectrum of the purified SMYD2 showed minima around 208 and 220 nm characteristic for af olded protein (Figure S1 Ai nt he Supporting Information) andt he obtained melting temperature of 55.9 8C (Figure S1 B) documented stable folding. SMYD2 activity was tested using peptideS POT arrays probing severalw ell-studied histonem ethylation marks together with p53-K370. To this end, 20-residue peptideswere synthesized on acellulose membrane using the SPOT technology. [36, 37] The resulting SPOT peptide arrays were incubated with SMYD2 using radioactively labelled AdoMet as cofactor and the transfer of radioactivelyl abelled methyl groups to p53 was detected by autoradiography ( Figure 1B ). Note that the differentp eptides equences could yield slightly different background signal levels due to unspecific bindingo fA doMet.T his experiment confirmed the methylationo fH 3K36 as shown by the clear methylation signal of the H3 28-48p eptide, which was completely lost after the K36A exchange. In the case of the H3 1-20 peptide, am ethylation signal was observed, which was decreased after the H3K4 exchange but not affected by the K9A exchange, indicating methylation of H3K4. However, the strongest methylation was observed on the p53 peptide, which was almostc ompletely lost after the K370A exchange demonstrating as tronga nd specific methylation of p53-K370 by SMYD2. The methylation activity of SMYD2 was next tested on the p53 protein using radioactively labeled AdoMet. The methylated reactionm ixture was separated using sodium dodecyls ulfate-polyacrylamide gel electrophoresis (SDS-PAGE) andt he transfer of radioactively labelledm ethyl groups to p53 was detected by autoradiography (Figure1C). The result revealed as trong methylation of p53, whereas no signalc ould be detected in the absence of p53.
Substrate specificity analysis of SMYD2
For specificity analysis, larger SPOT peptidel ibraries weres ynthesized by using the p53 sequence (363-377) as template, which was selected based on the strongm ethylation signal observed in Figure 1B .T he peptide arrays consisted of 300 individual peptides in each of which one amino acid of the original sequence was exchanged against one of the 20 natural amino acids generating all possible single amino acid exchanges of the template sequence. With this approach, the influence of each single amino acid at every position of the substrate peptideo nt he enzymatic activity of SMYD2 can be investigated in detail.T he peptide arrays were incubated with methylation buffer containing SMYD2 and radioactively labeled AdoMet as cofactor.T he transfer of methyl groups to the immobilized peptides was detected by autoradiography ( Figure 2A ). The experiment was conducted two times. Afterward, each array was quantified and the results of the two independent experiments were normalized and averaged ( Figure 2B ). Based on these data, the standard deviations (SD) were calculated for the methylation activity on each single spot to evaluate the quality of the peptidea rray methylation experiments.
As shown in Figure 2C ,t he SPOT peptidea rray methylation data were highly reproducible, because 87 %o ft he peptides showeda nS Ds maller than 20 %, around 97 %o ft he peptides showeda nS Ds maller than 30 %a nd only seven peptides had an SD larger than 30 %( Figure 2C ). Our data show that SMYD2 is specific towardaleucine at position À1o ft he substrate peptides equence (considering the target lysinea s0 ). It only weakly tolerates phenylalanine at the same site. SMYD2d id not exhibit specificity for amino acids N-terminal to position À1. At the + 1t o+ 3p ositions, polar uncharged and basic residues are preferred, buta cidic residues (aspartatea nd glutamate),c ysteine and large hydrophobic as well as aromatic residues were not tolerated to ad ifferent degree leadingt ot he followings pecificity profile:
Severalo ft he known non-histone targets, including p53 (SHLK 370 SKK, the template sequence of the peptide array), ERa (RMLK 266 HKR), Rb (RVLK 860 RSA), PARP1 (LTLK 528 GGA) and MAP-KAPK3 (KDLK 355 TSN) fit to the derived sequence motif, as well as the K36 methylation site (GGVK 36 KPH) on histone H3. The preference of SMYD2 for leucine and phenylalanine at the À1 site of the target peptidec an be explainedb yt he structure of the enzyme in complex with the p53 (PDB ID:3 S7F) [14] or ERa peptides (PDB ID:4 O6F). [19] In both structures, the corresponding target peptide leucine residue at the À1s ite is in close proximity to methyl groups of SMYD2 residues T105, L108, V179, and T185 and furtherc ontacted by the Ca of N180 and G183 and Cb of S196, altogether creating ah ydrophobic pocket large enough to accommodatealeucine residue (Figure 3A) . The disfavor for acidic residues at the + 1t o+ 3s ites in the target peptide can be explained by the close proximity of two acidic side chains from SMYD2 (E187 and D242) and the general acidic natureo ft he peptideb inding pocket ( Figure 3B ). Overall SMYD2s howedarelatively weak peptide sequence specificity with surprisingly little sequence specific readout.T his finding suggests that the methylation specificity of this enzymev ery likelyi sa lso controlled by substrate binding specificity at the protein level.
Methylation of non-histonep eptide substrates by SMYD2
Since we werei nterested to discover novel biological relevant substrates of SMYD2, the newly identified sequence motif was used to screen for potentialn ovel non-histone targets in the Figure 1 . Proteinpurificationa nd activity validation of SMYD2. A) Full-length SMYD2a nd p53 were cloned as GST-fusion proteins and purified by affinity chromatography.B)Methylation of peptideSPOTarrayscontaining the previously identified methylation sites of SMYD2 on H3, somea dditional well studiedh istone methylation sitesa nd the p53 methylation substrate. K-to-A peptides were included to identify the lysine residues that were methylated in the corresponding wild-type peptide. The lower part shows aq uantificationoft he spot intensities. C) Methylation of the purified p53 protein with radioactively labeled AdoMet. Methylateds amples were separated by SDS-PAGE andthe methylg roup transfer was detectedb ya utoradiography.After two days of exposure methylation of p53 could be detected, whereas in absenceo fp 53 no methylation was observed.
ChemBioChem 2020, 21,256 -264 www.chembiochem.org 2019 The Authors. Publishedb yWiley-VCH Verlag GmbH &Co. KGaA, Weinheim human proteome using Scansite( https://scansite4.mit.edu/). [38] Amongt he almost 8000 hits, 124 proteins with nuclear localization and important biological functions were selected for further analysis( Ta ble S1). To check if SMYD2 can methylate these predicted targets, 15-residue peptides were synthesized on a cellulose membrane using the SPOT synthesis method. The p53 peptidea nd an artificial peptidewith an optimized SMYD2 target sequence were included as positive controlsa nd their corresponding K-to-A mutants were used as negative controls. To compare the SMYD2 activity with the activity at the histone methylation sites, H3K4,H 3K36 and the corresponding K-to-A mutant peptides were included on the array as well. Figure 4A shows that SMYD2 can methylate about 40 peptides with same or higher activity than p53 indicating that about 1 = 3 of the predicted targets werem ethylated.T he other peptides were either weakly or not methylated at all. Out of these 40 substrates, 14 were selected for furtheri nvestigation based on their high methylation intensity.
To furtherd evelop the detection of possible novel substrates, the PhosphoSite Plus database( https://www.phosphosite.org/) [39] was used, whicha llows to identify proteins with known methylation within the broadened SMYD2 sequence motif [LF]-[K].W ith this approach, 155 methylation sites in non-histone proteins werei dentifiedw hich are methylated in cells at potential SMYD2 target sites (Table S2 ). All potential targets were synthesized as 15 amino acid long peptidesw ith the target lysine in the centero naS POT peptidea rray and treated as explained previously ( Figure 4B ). As before,t his [14] A) Residuesi nthe vicinity of the Leu at the À1p osition.T he peptide is showni nc yan with the side chain of the Leu residue in blue. SMYD2i ss hown in ribbonv iew (grey) with the interacting residues in red. Distances are indicated in .B )Electrostatic surface view of SMYD2i llustrating the dominanceo fa cidic residuesi nt he binding pocket.T he bound peptideiss howningreen.
ChemBioChem 2020, 21,256 -264 www.chembiochem.org array contained the sequence of p53 and the artificial peptide together with their K-to-A mutants as controls. Out of the 155 potentialn on-histone targets,1 9p eptides were methylated equallys trong as p53 or even stronger and weres elected for furtheri nvestigation.I nterestingly,t he more globals earch applied here, which did not include the information aboutt he + 1t o+ 3s ites, led to as ignificantly lower hit rate of only 12 %a sc ompared to 33 %f ound in the screen based on the full motif.
The 33 selected non-histone targets from both screens were synthesized on an additional peptideS POT array together with their K-to-A mutants to confirm that the predicted target lysine is methylated by SMYD2 ( Figure 4C ). Strikingly,f or 32 out of the 33 tested peptidesacomplete loss or strong decrease in the methylation signal was detected with the alanine mutant relative to the wild-type peptides ( Table 1 ). This shows that the target lysine is indeed methylated by SMYD2i ndicating an excellent power of the previous screens. Among the peptides with validated methylations ites, 24 were selected for furtherp rotein work based on their strong methylation and the known important biological functions of the corresponding proteins.
Methylation of non-histoneprotein substrates by SMYD2
After confirming the methylation of 32 peptides ubstrates, further methylation analysis of the validated substrates followed at protein level. Methylation of the targets at the protein level can differ from peptidel evel, because the target lysine may not be accessible in the context of the folded protein. The selected targetsw ere cloned as GST fusion proteins, overexpresseda nd purified by affinity chromatography.F or 18 of them purification was possible at sufficientq uality for the follow-up work ( Figure S2 ). Sequencing results of NFKBID revealed mutations and this target was excluded from further analysis. Roughly equal protein amountsw ere incubated with SMYD2 in methylation buffer containing radioactively labeled AdoMet.A fter methylation, the samples were separated on a 16 %S DS gel and the methyl group transfer was detected by autoradiography.A sp ositive control,t he p53 protein was included.The results showninFigure 5demonstrate that six proteins (AFF1, CENPW,T AF1, PHF20, FGD5 and RAPH1, marked with ar ed asterisk) were stronger methylated than p53. The methylation signals of three proteins (UHRF2, RAD18a nd CAP1, marked with blue asterisk) were similar to p53. For five proteins (TMUB1, CHD3, AGAP2, PHF2, and ELAC1, marked (Table S1 ). B) SPOT array methylation of candidate SMYD2 targets taken from the PhosphoSite Plus database(Ta ble S2). C) Selectedp eptides found to be methylatedi npanel Aand Bw ere synthesized on an additionalS POT peptide array together with their corresponding K-to-A mutants( Table 1) . On each array, the artificialpeptide and p53 peptide were included as positive controls. As negativec ontrols, the corresponding K-to-A mutants of the artificial peptide and p53 peptide were synthesized nexttot he corresponding wild-type spots. Spots marked with red circles in (C) were selected for further investigation of protein methylation.
ChemBioChem 2020, 21,256 -264 www.chembiochem.org with black asterisk) methylation was detected, but weaker than for p53. Only three of the proteins did not showd etectable methylation (RRN3,C LU3 and PolR2B), indicating an excellent overall success rate of the validation of peptide substrates in this analysis of 82 %.
Because we were mostly interested in targetsw ith strong methylation, verification of the predicted target lysinemethylation was performed for nine selected protein substrates (AFF1, CENPW,U HRF2, RAD18, TAF1, PHF20, CAP1, FGD5 and RAPH1; Ta ble 2). To this end, site-directed mutagenesis was performed to exchange the target lysine against arginine. The mutated proteins were overexpressed, purified by affinity chromatography and methylated as described before ( Figure 6 ). All K-to-R mutant non-histone targets (except RAPH1) exhibited al oss or strong decreasei nm ethylation relative to their corresponding wild-type proteins.I nt he case of FGD5, mutation of the predicated target lysine only led to ag radual decrease in methylation signal. The sequence of this protein contains two additional LK motif in close proximity to the predicted target lysine, but mutation of these two lysine residues did not lead to af urther decrease in the methylation signal (data not shown). Further investigation is necessary to detect which additional lysine residue of FGD5 is methylatedb yS MYD2. In the case of RAPH1, the initial mutation of the target lysine K134 did not lead to ad ecrease in methylation. This protein contains additional LK motifs and mutation of K129 to arginine led to ad ecreasei nm ethylation. Complete loss of methylation was achieved by combination of the K129R and K134R mutations indicating that SMYD2 methylates the predicted target lysine K134 but also K129.
In summary,m ethylationo ft he lysine residue predicted from peptides tudies was validated for all nine tested proteins. Three of them (CAP1, FGD5 and RAPH1) hadb een shown previously in proteomics screens to be methylated in cells at the SMYD2 target lysine identified here, but the PKMT responsible to introduce these methylations was not known.O ur data strongly suggest that these methylation events are catalyzed by SMYD2. The newly discovered SMYD2 substrates all have important biological functions in chromatin regulation (CENPW,P HF20, UHRF2, and RAD18), transcription (AFF1, Table 1 . List of potential novel non-histone targetsi dentified in Scansite search ( Figure 4A PHF20, TAF1), and intracellulars ignaling via ubiquitylation (UHRF2, RAD18), the Ras pathway (FGD5, RAPH1)o ro ther pathways (CAP1, AGAP2). Future studies will need to validate the SMYD2 dependentm ethylation of these proteins in cells and study its biological consequences.
Conclusions
It was the aim of this work to identify novel substrates of the SMYD2 PKMT.U sing peptide arrays, we investigated the substrate sequence specificity profile of the enzyme, revealing a rather low level of specificity,b ecause only at the À1s ite a real recognitiono fl eucine (or at weaker level phenylalanine) was detected. At the + 1t o+ 3s ites, some less specific additional effects were observed including the disfavor for acidic residues.U sing the derived sequence specificitym otif, novel SMYD2 peptides ubstrates were identified and, in as econd step, methylation at the target lysine was validated. Strikingly, high fractions of predicted SMYD2 peptides ubstrates were indeed found to be methylated, 33 %i nt he case of the full motif and still 12 %i nt he case of the reduced[ LF]-[K] motif. Our study has led to the discoveryo f3 2n ovel peptide sub- strates with validated target sites. Amongt hem, 19 were already reported to be methylated at the target lysine in human cells, strongly suggestingt hat SMYD2 is the PKMT responsible for these methylation events. Next, methylation of the novel substrates was tested at the protein level leading to the identification of 14 novel protein substrates of SMYD2. However,a s validation of protein methylation was very efficient for those proteins which could be successfully cloned, expressed and purified,i ti sv ery likely that many of the additional novel peptide substrates will also be methylatedb yS MYD2 at protein level. Six of the discovered protein substrates were methylated more strongly than p53, the best SMYD2 substrate described so far.T he novel SMYD2s ubstrate proteins are involved in diverse biological processes like chromatin regulation, transcription and different intracellular signaling pathways. Overall, our study boosts the number of known SMYD2 substrates considerably providing af undament for future studies to investigate the functiono ft he methylation of these novel SMYD2 substrates in cells.
Experimental Section
Cloning, expression, and purification of the proteins: SMDY2 was cloned as described. [14] The domains of the non-histone substrates and p53 were amplified by PCR using cDNA isolated from HEK293 cells as template. The amplified DNA was inserted into the pGEX-6p2 bacterial expression vector for protein expression. Protein domains of the non-histone substrates were predicted with the Scooby domain prediction tool (http://www.ibi.vu.nl/programs/ scoobywww/). [40] The different mutations were introduced by sitedirected mutagenesis. [41] All cloning steps were confirmed by sequencing. Protein overexpression was performed in BL21 DE3 Codon Plus cells (Novagen) in ampicillin containing lysogeny broth at 37 8Ct ill the main culture reached an OD 600 of 0.6. Afterward, protein expression was induced by the addition of 1mm isopropyl Peptide array synthesis and methylation: The peptide arrays were synthesized with an Autospot peptide array synthesizer (Intavis AG, Kçln, Germany) using the SPOT synthesis method. [36, 37] The arrays contain 15 or 20 amino acid long peptides immobilized on a cellulose membrane. After synthesis, the membrane was pre-incubated in methylation buffer (50 mm Tris·HCl pH 9, 100 mm NaCl, 5mm DTT) for 5min. Thereafter,t he membrane was incubated in methylation buffer supplemented with 0.76 mm radioactively labeled AdoMet (PerkinElmer) and 0.6 mm SMYD2 for 1hat 25 8Co n as haker.A fterward, the membrane was washed five times for 5min with wash buffer (100 mm NH 4 HCO 3 ,1%S DS), followed by the incubation in amplify NAMP100V (GE Healthcare) for 10 min. Then, the membrane was exposed to aH yperfilm high-performance autoradiography film (GE Healthcare) at À80 8Ci nt he dark for various periods of time and developed with ad eveloping machine.
Protein methylation assay: Protein methylation was performed using 5-10 mgo ft he substrate proteins in at otal volume of 40 mL methylation buffer (50 mm Tris·HCl pH 9, 100 mm NaCl, 5mm DTT) supplemented with 0.76 mm radioactive labeled AdoMet (Perkin-Elmer) and 0.6 mm SMYD2 for 3-8 ha t2 5 8C. The reactions were stopped by the addition of SDS loading buffer and incubation at 95 8Cf or 5min. Thereafter,t he samples were separated by 12 or 16 %S DS-PAGE. This step was followed by the incubation of the gel in amplify NAMP100V (GE Healthcare) for 45 min and drying of the gel in vacuum at 60 8Cf or 90 min. The dried SDS gel was then exposed to aH yperfilm high performance autoradiography film as described above.
Circular dichroism analysis: Circular dichroism (CD) spectra of SMYD2 were measured using aJ -815 circular dichroism spectrophotometer (Jasco) using 7 mm protein diluted in ab uffer containing 100 mm KCl. The spectra were measured in aw avelength range between 190 nm and 240 nm by using a0 .1 mm cuvette. The measurement was performed with an accumulation of 120 scans and as can speed of 200 nm min À1 .T he spectrum obtained with the dialysis buffer II was used as baseline. For the determination of the melting curve, 16 mm protein was used. The measurement was performed at aw avelength of 210 nm in the temperature range of 20 and 80 8Cu sing ah eating rate of 1 8Cmin À1 .T he obtained data was analyzed with Microsoft Excel as described. [42] Figure 6 . Validation of target lysine methylation of the novel SMYD2 protein substrates. Site directed mutagenesis was performed to create lysine to arginine mutants of the selected non-histone protein substrates. Similarp rotein amounts of the wild-type and K-to-R proteins were used for methylation experiments shown in the autoradiography images. For CENPW,black asterisks indicatethe protein bands that correspond to methylation signal. A) Nonhistone target protein domains and their K-to-R mutants identified in the Scansite search. B) Non-histonetarget protein domains and their K-to-R mutants identified in the PhosphoSite Plus database search of methylated proteins. Exposure of the autoradiography films was8hfor all targets, except RAPH1 (1 day)and CAP1, FGD5( 3days).
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